Tissue engineering: Viable technologies seeking regulation - A Finnish perspective

Drug Discovery Today

Volumn 9, Issue 9, 2004, Pages 387-391

  Nieminen, Outi ^a   Nordström, Katrina ^a   Kurki, Pekka ^b  

^a AALTO UNIVERSITY   (Finland)

^b NATIONAL AGENCY FOR MEDICINES   (Finland)

Author keywords

Biotechnology; Cell based therapy; Drug Discovery; Pharmaceutical Science; Regulation; Stem cell; Tissue engineering

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; FINLAND; HEALTH CARE ORGANIZATION; LITERATURE; PUBLICATION; REVIEW; RISK ASSESSMENT; STEM CELL; TISSUE ENGINEERING;

EID: 1842635477     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02938-6     Document Type: Note

References (6)

1. Chignon, T. (2003) Regulation of human tissue/cell products in Europe. Keynote Presentation, Regulatory Affairs Professional Services Discussion Forum: development and regulation of cell-based and related therapies (20-21 March 2003, London, UK) (unpublished)
2. Warner, J. (2003) The status of regulation of cell therapy products by the US FDA. Keynote Presentation, Regulatory Affairs Professional Services Discussion Forum: development and regulation of cell-based and related therapies (20-21 March 2003, London, UK) (unpublished)
3. Gee A.P. The impact of regulatory policy on the development of somatic cell therapies. Transpl. Immunol. 9:2002;295-300.
4. Hirsjarvi, S. and Hurme, H. (2000) Tutkimushaastattelu - Teemahaastattelun teoria ja käytäntö (1st edn), Yliopistopaino
5. Persidis A. Xenotransplantation. Nat. Biotechnol. 17:1999;205-206.
6. Dove A. Cell-based therapies go live. Nat. Biotechnol. 20:2002;339-343.